Analysis of drug interactions with modified proteins by high-performance affinity chromatography

Binding of glibenclamide to normal and glycated human serum albumin

Ryan Matsuda, Jeanethe Anguizola, K. S. Joseph, David S Hage

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

High-performance affinity chromatography (HPAC) was used to examine the changes in binding that occur for the sulfonylurea drug glibenclamide with human serum albumin (HSA) at various stages of glycation for HSA. Frontal analysis on columns containing normal HSA or glycated HSA indicated glibenclamide was interacting through both high affinity sites (association equilibrium constant, Ka, 1.4-1.9×106M-1 at pH 7.4 and 37°C) and lower affinity sites (Ka, 4.4-7.2×104M-1). Competition studies were used to examine the effect of glycation at specific binding sites of HSA. An increase in affinity of 1.7- to 1.9-fold was seen at Sudlow site I with moderate to high levels of glycation. An even larger increase of 4.3- to 6.0-fold in affinity was noted at Sudlow site II for all of the tested samples of glycated HSA. A slight decrease in affinity may have occurred at the digitoxin site, but this change was not significant for any individual glycated HSA sample. These results illustrate how HPAC can be used as tool for examining the interactions of relatively non-polar drugs like glibenclamide with modified proteins and should lead to a more complete understanding of how glycation can alter the binding of drugs in blood.

Original languageEnglish (US)
Pages (from-to)114-122
Number of pages9
JournalJournal of Chromatography A
Volume1265
DOIs
StatePublished - Nov 23 2012

Fingerprint

Drug interactions
Affinity chromatography
Glyburide
Drug Interactions
Affinity Chromatography
Serum Albumin
Proteins
Pharmaceutical Preparations
Digitoxin
Equilibrium constants
Blood
Binding Sites
Association reactions

Keywords

  • Drug-protein binding
  • Glibenclamide
  • Glycation
  • High-performance affinity chromatography
  • Human serum albumin

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Organic Chemistry

Cite this

Analysis of drug interactions with modified proteins by high-performance affinity chromatography : Binding of glibenclamide to normal and glycated human serum albumin. / Matsuda, Ryan; Anguizola, Jeanethe; Joseph, K. S.; Hage, David S.

In: Journal of Chromatography A, Vol. 1265, 23.11.2012, p. 114-122.

Research output: Contribution to journalArticle

@article{6c927e0575a246e184404aa885744288,
title = "Analysis of drug interactions with modified proteins by high-performance affinity chromatography: Binding of glibenclamide to normal and glycated human serum albumin",
abstract = "High-performance affinity chromatography (HPAC) was used to examine the changes in binding that occur for the sulfonylurea drug glibenclamide with human serum albumin (HSA) at various stages of glycation for HSA. Frontal analysis on columns containing normal HSA or glycated HSA indicated glibenclamide was interacting through both high affinity sites (association equilibrium constant, Ka, 1.4-1.9×106M-1 at pH 7.4 and 37°C) and lower affinity sites (Ka, 4.4-7.2×104M-1). Competition studies were used to examine the effect of glycation at specific binding sites of HSA. An increase in affinity of 1.7- to 1.9-fold was seen at Sudlow site I with moderate to high levels of glycation. An even larger increase of 4.3- to 6.0-fold in affinity was noted at Sudlow site II for all of the tested samples of glycated HSA. A slight decrease in affinity may have occurred at the digitoxin site, but this change was not significant for any individual glycated HSA sample. These results illustrate how HPAC can be used as tool for examining the interactions of relatively non-polar drugs like glibenclamide with modified proteins and should lead to a more complete understanding of how glycation can alter the binding of drugs in blood.",
keywords = "Drug-protein binding, Glibenclamide, Glycation, High-performance affinity chromatography, Human serum albumin",
author = "Ryan Matsuda and Jeanethe Anguizola and Joseph, {K. S.} and Hage, {David S}",
year = "2012",
month = "11",
day = "23",
doi = "10.1016/j.chroma.2012.09.091",
language = "English (US)",
volume = "1265",
pages = "114--122",
journal = "Journal of Chromatography",
issn = "0021-9673",
publisher = "Elsevier",

}

TY - JOUR

T1 - Analysis of drug interactions with modified proteins by high-performance affinity chromatography

T2 - Binding of glibenclamide to normal and glycated human serum albumin

AU - Matsuda, Ryan

AU - Anguizola, Jeanethe

AU - Joseph, K. S.

AU - Hage, David S

PY - 2012/11/23

Y1 - 2012/11/23

N2 - High-performance affinity chromatography (HPAC) was used to examine the changes in binding that occur for the sulfonylurea drug glibenclamide with human serum albumin (HSA) at various stages of glycation for HSA. Frontal analysis on columns containing normal HSA or glycated HSA indicated glibenclamide was interacting through both high affinity sites (association equilibrium constant, Ka, 1.4-1.9×106M-1 at pH 7.4 and 37°C) and lower affinity sites (Ka, 4.4-7.2×104M-1). Competition studies were used to examine the effect of glycation at specific binding sites of HSA. An increase in affinity of 1.7- to 1.9-fold was seen at Sudlow site I with moderate to high levels of glycation. An even larger increase of 4.3- to 6.0-fold in affinity was noted at Sudlow site II for all of the tested samples of glycated HSA. A slight decrease in affinity may have occurred at the digitoxin site, but this change was not significant for any individual glycated HSA sample. These results illustrate how HPAC can be used as tool for examining the interactions of relatively non-polar drugs like glibenclamide with modified proteins and should lead to a more complete understanding of how glycation can alter the binding of drugs in blood.

AB - High-performance affinity chromatography (HPAC) was used to examine the changes in binding that occur for the sulfonylurea drug glibenclamide with human serum albumin (HSA) at various stages of glycation for HSA. Frontal analysis on columns containing normal HSA or glycated HSA indicated glibenclamide was interacting through both high affinity sites (association equilibrium constant, Ka, 1.4-1.9×106M-1 at pH 7.4 and 37°C) and lower affinity sites (Ka, 4.4-7.2×104M-1). Competition studies were used to examine the effect of glycation at specific binding sites of HSA. An increase in affinity of 1.7- to 1.9-fold was seen at Sudlow site I with moderate to high levels of glycation. An even larger increase of 4.3- to 6.0-fold in affinity was noted at Sudlow site II for all of the tested samples of glycated HSA. A slight decrease in affinity may have occurred at the digitoxin site, but this change was not significant for any individual glycated HSA sample. These results illustrate how HPAC can be used as tool for examining the interactions of relatively non-polar drugs like glibenclamide with modified proteins and should lead to a more complete understanding of how glycation can alter the binding of drugs in blood.

KW - Drug-protein binding

KW - Glibenclamide

KW - Glycation

KW - High-performance affinity chromatography

KW - Human serum albumin

UR - http://www.scopus.com/inward/record.url?scp=84868129393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868129393&partnerID=8YFLogxK

U2 - 10.1016/j.chroma.2012.09.091

DO - 10.1016/j.chroma.2012.09.091

M3 - Article

VL - 1265

SP - 114

EP - 122

JO - Journal of Chromatography

JF - Journal of Chromatography

SN - 0021-9673

ER -